TY - JOUR
T1 - MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
AU - Lalla, Rajesh V.
AU - Bowen, Joanne
AU - Barasch, Andrei
AU - Elting, Linda
AU - Epstein, Joel
AU - Keefe, Dorothy M.
AU - McGuire, Deborah B.
AU - Migliorati, Cesar
AU - Nicolatou-Galitis, Ourania
AU - Peterson, Douglas E.
AU - Raber-Durlacher, Judith E.
AU - Sonis, Stephen T.
AU - Elad, Sharon
AU - AUTHOR GROUP
AU - Al-Dasooqi, Noor
AU - Brennan, Michael
AU - Gibson, Rachel
AU - Fulton, Janet
AU - Hewson, Ian
AU - Jensen, Siri B.
AU - Logan, Richard
AU - Öhrn, Kerstin E. O.
AU - Sarri, Triantafyllia
AU - Saunders, Deborah
AU - von Bültzingslöwen, Inger
AU - Yarom, Noam
N1 - With 12 collaborators of the Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO)
PY - 2014
Y1 - 2014
N2 - Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis. A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines. The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy
AB - Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis. A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines. The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy
U2 - https://doi.org/10.1002/cncr.28592
DO - https://doi.org/10.1002/cncr.28592
M3 - Review article
C2 - 24615748
SN - 0008-543X
VL - 120
SP - 1453
EP - 1461
JO - Cancer
JF - Cancer
IS - 10
ER -